EL7.AI पर प्रदान की गई जानकारी केवल शैक्षिक और सूचनात्मक उद्देश्यों के लिए है और यह वित्तीय सलाह नहीं है।
EL7.AI पर प्रदान की गई जानकारी केवल शैक्षिक और सूचनात्मक उद्देश्यों के लिए है और यह वित्तीय सलाह नहीं है।
GH Research PLC (Nasdaq: GHRS) announced the publication of Phase 2b clinical trial results for its lead candidate, GH001, in the prestigious journal JAMA Psychiatry. The study focuses on GH001 (Mebufotenin), a treatment designed for patients suffering from treatment-resistant depression (TRD). A significant new analysis revealed that the drug's efficacy remains consistent regardless of the number of prior treatment failures a patient has experienced. This finding suggests that GH001 could serve a broader range of patients within the TRD population, significantly enhancing its market potential. The peer-reviewed publication provides critical clinical validation for the company's therapeutic approach and its potential to change psychiatric practice. Investors view this development as a positive step toward the future regulatory and commercial success of GH Research.
इस कंटेंट को एक्सेस करने के लिए मुफ्त साइन अप करें
मुफ्त अकाउंट बनाएं